Zobrazeno 1 - 2
of 2
pro vyhledávání: '"María Verónica Ventriglia"'
Autor:
María Belén Sanchez, Bianca Vasconcelos Cordoba, Carolina Pavlovsky, Beatriz Moiraghi, Ana Varela, Rosario Custidiano, Isolda Fernandez, María Josefina Freitas, María Verónica Ventriglia, Georgina Bendek, Romina Mariano, María José Mela Osorio, Miguel Arturo Pavlovsky, Ana García de Labanca, Cecilia Foncuberta, Isabel Giere, Masiel Vera, Mariana Juni, José Mordoh, Julio Cesar Sanchez Avalos, Estrella Mariel Levy, Michele Bianchini
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionTreatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase is considered a safe option if suitable molecular monitoring is available. However, the question arises as to which factors can contribute to the ma
Externí odkaz:
https://doaj.org/article/c31cf40a2c9d4dd98ac2f1617ee73530
Autor:
Carolina Pavlovsky, Bianca Vasconcelos Cordoba, María Belén Sanchez, Beatriz Moiraghi, Ana Varela, Rosario Custidiano, Isolda Fernandez, Maria Josefina Freitas, Maria Verónica Ventriglia, Georgina Bendek, Romina Mariano, María José Mela Osorio, Miguel Angel Pavlovsky, Ana García de Labanca, Cecilia Foncuberta, Isabel Giere, Masiel Vera, Mariana Juni, Jose Mordoh, Julio Cesar Sanchez Avalos, Gerardo Cueto, Silvia Miranda, Estrella Mariel Levy, Michele Bianchini
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-4 (2023)
Abstract Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR
Externí odkaz:
https://doaj.org/article/8fe9929083cf47d5a46398245f9bd84d